Tonix Pharmaceuticals Holding Corp. Stock Prediction
AI-powered sentiment analysis and prediction trends for TNXP, updated each market day.
TNXP AI Sentiment
AI sees no strong directional signal for Tonix Pharmaceuticals Holding Corp. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Sector
Exchange
Market Cap
$184,670,213
Cap Tier
Employees
142
Headquarters
BERKELEY HEIGHTS, NJ
Listed Since
Feb. 13, 2009
Website
TNXP Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TNXP Volatility
Tonix Pharmaceuticals Holding Corp. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
